23/03/2026
Medical writing isn’t just “documents” anymore, it’s becoming a strategic capability at the intersection of regulation, data, and patient trust.
📈 Market momentum: The global medical writing market is projected to grow from ~$4.23B (2025) to ~$4.67B (2026) (~10.3% YoY CAGR).
• Patient-centric communication is now expected
Plain-language content is expanding fast, especially with EU expectations around layperson-friendly trial information.
• Rise of Real-World Evidence (RWE)
RWE is increasingly influencing submissions and scientific narratives, pushing stronger integration of RWD/RWE insights into regulatory documents.
• GCP modernization (ICH E6(R3))
With ICH E6(R3) adopted on 06 Jan 2025, teams are strengthening traceability, quality-by-design language, and oversight documentation across clinical deliverables.
• Structured content & digital-ready protocols (ICH M11)
Movement toward structured protocol templates and technical specs is driving modular content, reuse, and consistency across studies.
• AI-augmented workflows (with governance)
AI can speed up drafting and QC, but the differentiator is compliant processes, review discipline, and audit-ready outputs.
If you’re scaling submissions, tightening timelines, or aligning to evolving guidance, QInscribe can support end-to-end regulatory and clinical writing, from protocols and CSRs to CTD summaries, transparency deliverables, and standalone QC.
Enquire now: https://hubs.li/Q046SWQZ0
📩 info@qinscribe.com